Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Shire plc | dp44188_8k.htm |
Exhibit 99.1
|
Press Release
|
 |
|
www.shire.com
|
Director’s Share Dealings
February 21, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) announces it was notified on February 20, 2014 that on that day, Matthew Emmens, the Company’s Chairman, sold 36,100 Ordinary Shares in the Company (“Shares”) at an average sale price of £33.14853. The Shares were sold on the London Stock Exchange.
Following the above transaction, Mr Emmens holds 56,774 Shares and 5,872 American Depositary Shares in the Company (“ADSs”). Each ADS represents three Shares.
This notification is to satisfy the Company’s obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
|
Investor Relations
|
||
|
Laurie Stelzer
|
lstelzer@shire.com
|
+1 858 754 5480
|
|
Eric Rojas
|
erojas@shire.com
|
+1 781 482 0999
|
|
Sarah Elton-Farr
|
seltonfarr@shire.com
|
+44 1256 894157
|
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas.
www.shire.com
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX